KROS
Keros Therapeutics, Inc.
Biotechnology · Healthcare · United States
11.36
close · 2026-10-29
value
81
cheaper than peers81
quality
32
stronger fundamentals32
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.86× | 88 |
| EV to EBITDA | 0.32× | 84 |
| price to sales | 14.72× | 46 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -17.2% | 73 |
| debt to equity | 6.0% | 71 |
| operating margin | -655.8% | 29 |
| revenue growth | -99.8% | 0 |
4 of 4 measures available
Facts
| market cap | $225M |
| free cash flow | -$27.2M |
| employees | 92 |
| first trade | 2020-04-08 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.30 | -5.00 | -5.20 | -4.15 |
| free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M |
| net income | $87.0M | -$187.4M | -$153.0M | -$104.7M |
| revenue | $244.1M | $3.5M | $151,000 | $0 |
| unusual items | $24.9M | $23.5M | $14.8M | $3.6M |